Alnylam Pharmaceuticals, Inc. (ALNY) vs Royalty Pharma PLC (RPRX)

Alnylam Pharmaceuticals, Inc. and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $34.4B against $31.2B — 1.1× the size. Royalty Pharma PLC trades at the lower P/E: 40.1× against 43.6×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against 10.0%. Royalty Pharma PLC has the higher net margin (32.0% vs 16.1%) and the higher return on invested capital (5.28% vs 0.00%). Both pay a dividend; Royalty Pharma PLC yields more (3.09% vs 2.52%). Across the 23 metrics below, Royalty Pharma PLC leads on 12 and Alnylam Pharmaceuticals, Inc. on 11.